Financial Performance - The company reported a basic earnings per share of 0.0000 yuan for Q1 2025, a significant improvement from -0.0400 yuan in Q1 2024, marking a 100% increase [1] - Net profit for Q1 2025 was 0.01 billion yuan, compared to a loss of 0.19 billion yuan in Q1 2024, representing a 105.26% increase [1] - Operating revenue for Q1 2025 was 2.08 billion yuan, up 4% from 2 billion yuan in Q1 2024 [1] - The return on equity (ROE) improved to 0.50% in Q1 2025 from -6.84% in Q1 2024, indicating a 107.31% increase [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 15,177.04 million shares, accounting for 29.87% of the circulating shares, with a slight increase of 9.92 million shares from the previous period [1] - The largest shareholder, Guangzheng Investment Co., Ltd., holds 12,916.87 million shares, representing 25.41% of the total share capital, with no change in holdings [2] - New entrants among the top shareholders include Lin Yande, Hao Caiming, and Hao Chengxiang, while Xun Yanhong, Qiu Wanshu, and Luo Wenhua have exited the top ten list [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

光正眼科（002524）公告，2024年营业收入8.93亿元，同比下降16.94%。归属于上市公司股东的净亏损 1.75亿元，去年同期净利润925.5万元。基本每股收益-0.34元/股。公司计划不派发现金红利，不送红 股，不以公积金转增股本。 ...